AAIC 2023: New Alzheimer's data from TauRx sees reduction in neurodegeneration

17 July 2023
taurx-large

On Sunday, Singapore-headquartered TauRx Pharmaceuticals presented new data from the Phase III LUCIDITY trial that measured the impact of the company’s drug candidate, hydromethylthionine mesylate (HMTM), on neurofilament light chain (NfL), an established biomarker for brain neurodegeneration.

The results were presented during an oral presentation at the Alzheimer’s Association International Conference (AAIC) in Amsterdam, Netherlands.

TauRx noted that the blood concentration of NfL showed a statistically-significant 93% reduction in change over 12 months in participants receiving HMTM at a dose of 16mg/day relative to the control group, which correlated significantly with a tau biomarker (p-tau 181) in blood.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical